Abstract Number: 1420 • 2013 ACR/ARHP Annual Meeting
Induction Therapy With Adalimumab On Top Of An Aggressive Treat-To-Target Strategy With Methotrexate and Intraarticular Corticosteroid Reduces Radiographic Erosive Progression In Early Rheumatoid Arthritis, Even After Withdrawal Of Adalimumab. Results Of a 2-Year Trial (OPERA)
Background/Purpose: In a randomized double-blind, placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis¹ (RA) we aimed to investigate if additional adalimumab (ADA) for…Abstract Number: 1218 • 2013 ACR/ARHP Annual Meeting
Incidence Of and Risk Factors For Clinical Fractures In Patients With Systemic Lupus Erythematosus and Matched Controls: A Population-Based Study In The United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) has been associated with an increased risk of low bone mineral density and fractures. However, data on absolute fracture risk…Abstract Number: 1045 • 2013 ACR/ARHP Annual Meeting
Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis
Background/Purpose: Oral glucocorticoid (GC) therapy is used in more than half of patients with rheumatoid arthritis (RA). Cataracts are a recognised treatment-related side effect of…Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…Abstract Number: 103 • 2013 ACR/ARHP Annual Meeting
Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 2010 ACR Recommendations On Glucocorticoid-Induced Osteoporosis
Background/Purpose: Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. Fracture related to GIO increases a patient’s mortality risk and reduces quality of…Abstract Number: 2352 • 2012 ACR/ARHP Annual Meeting
Temporal Artery Biopsy Culture in Tridimensional Matrix. an in Vitro Model for Functional Studies in Giant-Cell Arteritis
Background/Purpose: GCA is the most frequent systemic vasculitis in Europe and North America. In spite of the initial response to glucocorticoid treatment more than 60%…Abstract Number: 228 • 2012 ACR/ARHP Annual Meeting
Simultaneous Initiating of Glucocorticoids and disease-Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early
Background/Purpose: Glucocorticoids are the cornerstone of therapy in patients with polymyositis (PM) and dermatomyositis (DM). However, side effects are common. Furthermore, glucocorticoids exhibits an…Abstract Number: 2169 • 2012 ACR/ARHP Annual Meeting
Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose-Response Analysis of Randomized Controlled Trials
Background/Purpose: Concerns regarding Adverse Effects (AEs) often dominate decisions on applying Glucocorticoid (GC) therapy. Evidence of AEs is mainly based on observational data without proper…Abstract Number: 50 • 2012 ACR/ARHP Annual Meeting
Human Chondrocyte Dedifferentiation Is Accompagnied by CD105 Endoglin Expression, ALK-1/Smad1/5 Phosphorylation and Leptin Production – Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor
Background/Purpose: Leptin, mainly produced by the adipose tissue including fat neighboring the joint, is considered as pro-inflammatory in osteoarthritis (OA). Normal cartilage does not…Abstract Number: 2155 • 2012 ACR/ARHP Annual Meeting
The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset
Background/Purpose : A previous meta-analysis by Graudal and Jürgens (Arthritis Rheum. 2010;62:2852–63) challenged the belief that biologics better protect rheumatoid arthritis (RA) from joint destruction…Abstract Number: 36 • 2012 ACR/ARHP Annual Meeting
Role of FK506 Binding Protein 5 in Osteoclast Differentiation
Background/Purpose: RA is a chronic, systemic inflammatory disease characterized by the destruction of bone in the joints. Moreover, it is well appreciated that systemic osteoporosis…Abstract Number: 2085 • 2012 ACR/ARHP Annual Meeting
T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo
Background/Purpose: The role of endogenous glucocorticoids (GC) in, and their contribution to the susceptibility and severity of rheumatoid arthritis remains inconclusive. We previously demonstrated that…Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
ACR Meeting Abstracts